mIDH Gliomas Explained: Characteristics and Management Strategies

Guest: Rosaline Quinlivan From sustained therapy and emergency planning to psychological support, coordinated care is essential as patients with Duchenne muscular dystrophy (DMD) transition into adulthood. Explore multidisciplinary approaches to optimize function, independence, and quality of life in adults with DMD with Dr. Rosaline Quinlivan, Professor of Neuromuscular Disease at University College London.

Guest: Rosaline Quinlivan As patients with Duchenne muscular dystrophy (DMD) transition from pediatric to adult care, they may encounter healthcare professionals—from primary care to emergency medicine—without prior experience managing their condition. Explore critical gaps in adult services for DMD and gain practical insights to help deliver timely, informed, and compassionate care with Dr. Rosaline Quinlivan, Professor of Neuromuscular Disease at University College London.

Guest: Andrew J. Solomon, MD Accurately diagnosing multiple sclerosis (MS) involves understanding the diagnostic criteria, recognizing red flags to avoid misdiagnosis, and keeping up with new tools. Dr. Andrew Solomon, Professor and Interim Chair of the Department of Neurological Sciences and Chief of the Multiple Sclerosis Division at the University of Vermont, walks through the most difficult aspects of diagnosing patients with MS and potential breakthroughs reshaping how we approach these challenges. Dr. Solomon also spoke about this topic at the 2025 American Academy of Neurology Annual Meeting.

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Jason Ackrivo, MD, MSCE Guest: Bethany Lussier, MD Respiratory decline in patients with neuromuscular diseases and mitochondrial myopathies can be challenging to identify, especially because its early signs may be subtle and vary from person to person. However, knowing how to evaluate a patient’s respiratory function is key to improving outcomes and quality of life. Joining Dr. Charles Turck to discuss this importance and provide recommendations for optimizing respiratory care are Drs. Jason Ackrivo and Bethany Lussier. Dr. Ackrivo is an Assistant Professor of Medicine in Pulmonary, Allergy, and Critical Care at the Hospital of the University of Pennsylvania, and Dr. Lussier is an Associate Professor of Internal Medicine at UT Southwestern Medical Center and a member of its Division of Pulmonary and Critical Care Medicine.

Guest: Prajwal Ciryam, MD, PhD Traumatic brain injuries (TBIs) trigger a rapid transcriptional response in the choroid plexus, dominated by chemokines that attract neutrophils. Join Dr. Prajwal Ciryam, Assistant Professor of Neurology at the University of Maryland School of Medicine, as he explains how this early signaling may represent a critical window for modulating inflammation in the injured brain. Dr. Ciryam also spoke about this topic at the 2025 American Academy of Neurology Annual Meeting.

Guest: Kelly Sloane, MD For patients who experience aphasia after a stroke, intervention and social support are crucial for recovery. Dr. Kelly Sloane, Assistant Professor of Neurology at the University of Pennsylvania, highlights how timely therapy and strong support systems can help rebuild both language and confidence in these patients. Dr. Sloane also spoke about this topic at the 2025 American Academy of Neurology Annual Meeting.

Guest: Jennie Taylor, MD Defined by the production of 2-hydroxyglutarate, mutant isocitrate dehydrogenase (mIDH) gliomas are diffuse, slow-growing tumors. Managing these tumors requires personalized strategies that consider resectability, histology, and long-term treatment impacts. Dr. Jennie Taylor, Assistant Professor of Neurology and Neurological Surgery at the University of California San Francisco, explains the complexities behind this type of tumor and implications for patient care. Dr. Taylor also spoke about this topic at the 2025 American Academy of Neurology Annual Meeting.

Guest: Jennie Taylor, MD The FDA approval of vorasidenib marks a new era for mutant isocitrate dehydrogenase (mIDH) gliomas. Approved in 2024 for grade 2 tumors after surgery, it doubled progression-free survival in the INDIGO trial. Dr. Jennie Taylor, Associate Professor of Neurology and Neurological Surgery at the University of California San Francisco, dives into the data and explains what questions remain about long-term use and broader applications.

Guest: Beth Ann Malow, MD, MS The impacts of climate change present a growing threat to brain health. Rising heat, air pollution, and oxidative stress appear to worsen conditions like stroke, dementia, and multiple sclerosis. Join Dr. Beth Malow as she outlines the essential role clinicians play in prevention and education. Dr. Malow is a Professor of Neurology and Pediatrics and the Vice Chair for Academic Affairs in the Department of Neurology at Vanderbilt University Medical Center.

Guest: Lauren Schaff, MD Glioblastomas are fast, aggressive, and resistant to many standard therapies. Dr. Lauren Schaff, a neuro-oncologist at Memorial Sloan Kettering Cancer Center, explains how new molecular understandings and treatment avenues are paving the way for a more personalized, hopeful approach to care.